Syndax Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback